Centre National De La Recherche Scientifique

Université De Poitiers

Institut National De La Sante Et De La Recherche Medicale

Sorbonne Université

Universite Claude Bernard – Lyon1

Université Victor Segalen—bordeaux 2

Yvette Mettey

Jean Michel Vierfond

Jean-Michel Vierfond

Laurent Meijer

Peter Gregory Goekjian

Frédéric Becq

Marie-Thérèse Dimanche-Boitrel

Bernard Verrier

Stéphane Bach

Claire Delehouze

Marc Blondel

Christophe Cullin

Arnaud Comte

Laurence Pignoux

Christian Rogier

Michel Joffre

Cécile Marivingt-Mounir

Fr&eacute;d&eacute;ric Becq

Maurice Gola

Stephane Bach

Nicolas Talarek

Renaud Robert

The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation. 

Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis

The invention concerns screening molecules with anti-prion activity. More particularly, it concerns kits for screening molecules with anti-prion activity characterized in that they comprise in combination a [PSI+], phenotype yeast, an antibiogram and an agent for purifying prions at sub-efficient doses, said yeast including the adel-14 allele of the ADE1 gene and an inactivated ERG6 gene, the screening methods, and a family of molecules with anti-prion activity isolated by the inventive screen. The invention is applicable to anti-prion agents for producing medicines in particular for treating neurodegenerative diseases involving protein aggregates.

Screening molecules with anti-prion activity: kits, methods and screened molecules

The invention relates to pyrrolo[2,3b]-pyrazine derivatives having the general Formula (I) wherein R2 and R3 are identical or different and represent H, C1-C6 alkyl, said alkyl being a straight or branched-chain alkyl, which can be substituted, R6 is an optionally substituted aromatic cycle Ar or a cycloalkyl, said cycloalkyl being optionally substituted by an aryl group which can also be substituted, R7 is H, C1-C6 alkyl, (alk.)n-hal., CH2-CH&#x2550;CH2, CH2-cycloalkyl, CH2-Ar, with 'alk.' being a C1-C6 alkylene group, n being 1-6, Z is H or CH3. Application as active principle of pharmaceutical compositions, particularly for treating or preventing neurodegenerative disorders and proliferative disorders.

Derivatives of pyrrolo-pyrazines having a kinase inhibitory activity and their biological applications

The invention relates to the use of benzo[c]quinolizinium derivatives for treating diseases that are linked to smooth muscle cell constriction, such as hypertension and asthma.

Use of benzo[c]quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction

CFTR channel activator compounds from the benzo&lsqb;c&rsqb;quinolizinium family or families of compounds derived therefrom, as well as pharmaceutical compositions containing said compounds, and the uses thereof, particularly for treating cystic fibrosis, are disclosed.

CFTR channel activator compounds and pharmaceutical compositions containing same

Growing community of inventors

Poitiers, France

Yvette Mettey